Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Arcutis Biotherapeutics Inc

ARQT
Current price
8.15 USD +0.19 USD (+2.39%)
Last closed 7.96 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 943 476 544 USD
Yield for 12 month -13.67 %
1Y
3Y
5Y
10Y
15Y
ARQT
21.11.2021 - 28.11.2021

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California. Address: 3027 Townsgate Road, Westlake Village, CA, United States, 91361

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

19 USD

P/E ratio

Dividend Yield

Current Year

+59 606 000 USD

Last Year

+3 686 000 USD

Current Quarter

+49 569 000 USD

Last Quarter

+13 526 000 USD

Current Year

+53 488 000 USD

Last Year

+2 932 000 USD

Current Quarter

+46 313 000 USD

Last Quarter

+11 082 000 USD

Key Figures ARQT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -194 942 000 USD
Operating Margin TTM -63.79 %
PE Ratio
Return On Assets TTM -28.62 %
PEG Ratio
Return On Equity TTM -119.24 %
Wall Street Target Price 19 USD
Revenue TTM 106 394 000 USD
Book Value 1.95 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 1682.4 %
Dividend Yield
Gross Profit TTM 2 932 000 USD
Earnings per share -2.79 USD
Diluted Eps TTM -2.79 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY
Profit Margin -204.36 %

Dividend Analytics ARQT

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ARQT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation ARQT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 18.5294
Price Sales TTM 19.6743
Enterprise Value EBITDA -4.8485
Price Book MRQ 13.2

Financials ARQT

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators ARQT

For 52 weeks

1.76 USD 13.17 USD
50 Day MA 8.86 USD
Shares Short Prior Month 22 173 654
200 Day MA 6.34 USD
Short Ratio 7.45
Shares Short 24 640 193
Short Percent 23.76 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

446.34 USD Microsoft Corporation -3.37 (-0.75%)
Detailed analytics

ETF funds


S

SLICHA

203.95 CHF UBS SLI A-dis -0.06 (-0.02%)
Detailed analytics

Metals


Gold

2339.94 USD Gold +11.09 (+0.48%)
Detailed analytics